IPO Price History
Closed
Goldline Pharmaceutical Ltd. logo

Goldline Pharmaceutical Ltd. IPO

SME IPOListedBSE:544759BSE SME
Current Market Price (CMP)
₹36.60(-14.88%)
Current Price (CMP)
₹36.60(-14.88%)

Live Market Quote

Listing Price & Gain
₹56.77(+32.02%)

Day 1 Exchange Open

IPO Issue Price
₹43

Final Cut-off

Total Subscription
781.85x

Overall Bid Demand

Total Issue Size
₹11.02 Cr

Gross Public Offer

IPO Schedule & Key Dates

IPO Bidding Opens
12 May 2026
IPO Bidding Closes
14 May 2026
Allotment & Refunds
Completed
Exchange Listing Day
19 May 2026

IPO Subscription Status

Breakdown of institutional, high-net-worth, and retail bidding demand

Overall Demand: 781.85x
Investor CategorySubscriptionDemand Scale
Qualified Institutional Buyers (QIB)180.22x
Non-Institutional Investors (NII / HNI)1227.9x
Retail Individual Investors (RII)881.15x
Total Subscription781.85x
As on 2026-05-14

Listing Day & Return Performance

Listing Day Gain+32.02%
₹43 (Issue) → ₹56.77 (List)
Per share profit: +₹13.77
Holding Return (Till Date)-14.88%
₹43 (Issue) → ₹36.60 (CMP)
Net gain per share: ₹-6.40
Post-Listing Performance (Listing Day → Today):-35.53%

About Goldline Pharmaceutical Ltd. IPO

Goldline Pharmaceutical Ltd. is an Indian public offering categorized under the SME (Small and Medium Enterprise) segment. The public issue opened for bidding on 12 May 2026 and concluded on 14 May 2026, offering equity shares to institutional, non-institutional, and retail investors with an indicative price band of ₹43 per share. The aggregate issue size was approximately ₹11.02 crore.

During the bidding window, Goldline Pharmaceutical Ltd. witnessed heavy demand with an overall subscription of 781.85 times. Institutional investors (QIB) subscribed 180.22x, non-institutional high-net-worth investors (NII) subscribed 1227.9x, and retail individual investors (RII) bid 881.15x their reserved quota.

The equity shares of Goldline Pharmaceutical Ltd. officially debuted on the stock exchanges on 19 May 2026 at an opening listing price of ₹56.77, delivering a listing day return of +32.02% (premium) over the final issue price. As per the latest market data, the stock trades at ₹36.60, representing an overall decline of -14.88% since its IPO allotment.

Frequently Asked Questions

What was the issue price or price band of Goldline Pharmaceutical Ltd. IPO?
The issue price of Goldline Pharmaceutical Ltd. IPO was fixed at ₹43 per equity share. The indicative bidding price band was ₹43 per share.
What was the total issue size of Goldline Pharmaceutical Ltd. IPO?
The total issue size of Goldline Pharmaceutical Ltd. IPO was approximately ₹11.02 crore.
What were the open, close, and listing dates for Goldline Pharmaceutical Ltd. IPO?
Goldline Pharmaceutical Ltd. IPO opened on 12 May 2026, closed on 14 May 2026, listed on 19 May 2026.
How much was Goldline Pharmaceutical Ltd. IPO subscribed?
The IPO received an overall subscription of 781.85 times. Category-wise, QIBs subscribed 180.22x, NIIs subscribed 1227.9x, and Retail investors subscribed 881.15x.
What was the listing price and listing gain of Goldline Pharmaceutical Ltd. IPO?
Goldline Pharmaceutical Ltd. IPO listed on the stock exchange at ₹56.77, delivering a listing gain of 32.02% compared to the IPO issue price of ₹43.
Is Goldline Pharmaceutical Ltd. IPO a Mainboard or SME IPO?
Goldline Pharmaceutical Ltd. IPO is a SME IPO listed on the SME platform of BSE SME.
What is the current return of Goldline Pharmaceutical Ltd. IPO since its IPO?
At the latest market quote of ₹36.60, Goldline Pharmaceutical Ltd. IPO has generated an all-time return of -14.88% since its initial public offering.

Related SME IPOs (2026)

SAIURJA
Sai Urja Indo Ventures Ltd.
₹113+18.41%
SKOFFSET
S.K.Offset Ltd.
₹125+0.80%
HNIL
Himalaya Nutravedics India Ltd.
₹106+11.32%
ANAND
Anand Seamless Ltd.
₹72+0.14%